Navigation Links
MDS Nordion Begins to Manufacture Cardiac Imaging Agent

    Bracco's Cardiogen-82(R) Enables Cardiologists to Better Detect
    Cardiovascular Disease

OTTAWA, June 10 /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, today announced that it has commenced the manufacture of CardioGen-82(R) (Rubidium-82 generators), for Bracco Diagnostics, Inc. (part of Bracco Group), one of the world's leading companies in the imaging agent business.

MDS Nordion has designed and built a dedicated manufacturing suite within its world-class, U.S. Food and Drug Administration (FDA)-approved, Good Manufacturing Practices (GMP)-compliant production facility in Ottawa. Production of CardioGen-82 began yesterday.

CardioGen-82, the only generator-based, cardiac Positron Emission Tomography (PET) perfusion imaging agent approved by the FDA, produces Rubidium-82, using a specialized generator technology. Once administered to the patient, Rubidium-82 is used as a PET imaging tracer for perfusion studies of the heart to examine blood flow through heart vessels. PET is a highly sensitive medical imaging technique that produces a three-dimensional image of the functioning heart, allowing the cardiologist to identify regions of the heart muscle receiving poor blood flow.

"There is growing interest in advanced molecular imaging technologies to help better diagnose and treat disease," said Steve West, President of MDS Nordion. "MDS Nordion provides a full spectrum of services for the development and commercialization of novel radiopharmaceuticals. For more than 10 years, companies like Bracco have been relying on our proven track record for innovative solutions, quality, and reliability that make MDS Nordion the partner of choice."

A 2007 Frost & Sullivan report entitled U.S. PET and PET-CT (Computerized Tomography) Imaging Equipment Markets indicated that use of PET imaging as a diagnostic tool is on the rise. For the period 2007-2014, the report projects a total compounded annual growth rate of 17.3% for PET and PET-CT.

"This is an important milestone in the development of Bracco's innovative cardiac imaging technology and the new MDS facility provides Bracco with a world-class manufacturing capability with significant capacity for future expansion to meet anticipated market growth," said Carlo Medici, President and Chief Executive Officer of Bracco Diagnostics, Inc. "MDS Nordion's unique expertise in the development and manufacture of radiopharmaceuticals, along with its highly specialized facilities, made them an obvious choice when Bracco looked to expand its CardioGen-82 production capacity."

MDS Nordion offers tailored solutions, leading expertise and service capabilities for radiopharmaceutical development, clinical and commercial manufacturing, and radiation-based medical device development. MDS Nordion has GMP-compliant facilities in Ottawa and Vancouver, Canada, and Fleurus, Belgium that can accommodate a variety of development, manufacturing, and supply requirements.

About Bracco Imaging S.p.A.

Bracco Imaging S.p.A. is one of the world's leading companies in the diagnostic imaging business. Bracco Imaging develops, manufactures, and markets diagnostic imaging agents and solutions that meet medical needs and facilitate clinical solutions. Headquartered in Milan, Italy, Bracco Imaging operates in over 80 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses, and distribution partnership agreements.

Bracco Imaging is a subsidiary of Bracco S.p.A., the holding company of the Bracco Group which also markets ethical and over-the-counter (OTC) pharmaceutical products in Italy as well as advanced medical technology systems worldwide. Furthermore, the Bracco Group offers diagnosis services through the Milan-based Centro Diagnostico Italiano (Italian Diagnostic Center). For more information, visit

About MDS Nordion

MDS Nordion, a business unit of MDS Inc., is a global leader in providing medical isotopes for molecular and diagnostic imaging, radiotherapeutics, and sterilization technologies for medical products that benefit the lives of millions of people in more than 50 countries around the world. MDS Nordion products and services are used on a daily basis by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics, and research laboratories. Find out more at

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,000 highly skilled people in 29 countries. Find out more at or by calling 1-888-MDS-7222, 24 hours a day.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage
2. MDS Nordion Opens New Radiopharmaceutical Production Facility in Belgium
3. MDS Nordion Provides Update on AECLs Medical Isotope Supply Disruption
4. MDS Nordion Launches Improved TheraSphere(R) Administration System for Physicians
5. Dr. Peter Covitz Joins MDS Nordion as Senior Vice-President Innovation
6. MDS Nordion Provides Update to Medical Isotope Customers
7. MDS Nordion Divests Non Strategic Product Lines
8. MDS Nordion signs 17-year contract with Rosenergoatom
9. Par Pharmaceutical Begins Shipment of Generic Miacalcin(R)
10. Thomas R. Frieden, M.D., M.P.H., Begins Role as CDC Director and ATSDR Administrator
11. NTS Begins Testing for ZigBee RF4CE Specification
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: